ABCDEG Stress Echocardiography in Aortic Stenosis.

Quirino Ciampi, Lauro Cortigiani, Maria Rivadeneira Ruiz, Andrea Barbieri, Fiore Manganelli, Fabio Mori, Maria Grazia D'Alfonso, Francesca Bursi, Bruno Villari
Author Information
  1. Quirino Ciampi: Cardiology Division, Fatebenefratelli Hospital, 82100 Benevento, Italy. ORCID
  2. Lauro Cortigiani: Cardiology Division, San Luca Hospital, 55100 Lucca, Italy. ORCID
  3. Maria Rivadeneira Ruiz: Cardiology Division, Virgen Macarena University Hospital, 41009 Sevilla, Spain.
  4. Andrea Barbieri: Department of Biomedical, Cardiology Division, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41121 Modena, Italy. ORCID
  5. Fiore Manganelli: Cardiology Division, San Giuseppe Moscati Hospital, 83100 Avellino, Italy.
  6. Fabio Mori: Cardiology Division, Careggi Hospital, 50134 Florence, Italy.
  7. Maria Grazia D'Alfonso: Cardiology Division, Careggi Hospital, 50134 Florence, Italy.
  8. Francesca Bursi: Department of Health Science, University of Milan, Cardiology Division, San Paolo Hospital, ASST Santi Paolo e Carlo, 20142 Milano, Italy. ORCID
  9. Bruno Villari: Cardiology Division, Fatebenefratelli Hospital, 82100 Benevento, Italy.

Abstract

Rest and stress echocardiography (SE) plays a pivotal role in the evaluation of valvular heart disease. The use of SE is recommended in valvular heart disease when there is a mismatch between resting transthoracic echocardiography findings and symptoms. In aortic stenosis (AS), rest echocardiographic analysis is a stepwise approach that begins with the evaluation of aortic valve morphology and proceeds to the measurement of the transvalvular aortic gradient and aortic valve area (AVA) using continuity equations or planimetry. The presence of the following three criteria suggests severe AS: AVA < 1.0 cm, a peak velocity > 4.0 m/s, or a mean gradient > 40 mmHg. However, in approximately one in three cases, we can observe a discordant AVA < 1 cm with a peak velocity < 4.0 m/s or a mean gradient <40 mmHg. This is due to reduced transvalvular flow associated with LV systolic dysfunction (LVEF < 50%) defined as "classical" low-flow low-gradient (LFLG) AS or normal LVEF "paradoxical" LFLG AS. SE has an established role in evaluating LV contractile reserve (CR) patients with reduced LVEF. In classical LFLG AS, LV CR distinguished pseudo-severe AS from truly severe AS. Some observational data suggest that long-term prognosis in asymptomatic severe AS may not be as favorable as previously thought, offering a window of opportunity for intervention prior to the onset of symptoms. Therefore, guidelines recommend evaluating asymptomatic AS with exercise stress in physically active patients, particularly those younger than 70 years, and symptomatic classical LFLG severe AS with low-dose dobutamine SE. A comprehensive SE assessment includes evaluating valve function (gradients), the global systolic function of the LV, and pulmonary congestion. This assessment integrates considerations of blood pressure response, chronotropic reserve, and symptoms. StressEcho 2030 is a prospective, large-scale study that employs a comprehensive protocol (ABCDEG) to analyze the clinical and echocardiographic phenotypes of AS, capturing various vulnerability sources which support stress echo-driven treatment strategies.

Keywords

References

  1. J Am Coll Cardiol. 2018 Feb 6;71(5):475-485 [PMID: 29406851]
  2. J Clin Med. 2021 Mar 24;10(7): [PMID: 33805111]
  3. Circ Cardiovasc Interv. 2013 Dec;6(6):604-14 [PMID: 24221391]
  4. Circulation. 2006 Jul 4;114(1 Suppl):I553-8 [PMID: 16820636]
  5. Int J Cardiol. 2013 Sep 30;168(2):1683-4 [PMID: 23601214]
  6. Circ Cardiovasc Imaging. 2016 Jul;9(7): [PMID: 27406843]
  7. Eur Heart J. 2020 Jan 14;41(3):407-477 [PMID: 31504439]
  8. Biomed Res Int. 2013;2013:235194 [PMID: 24024185]
  9. Eur J Heart Fail. 2009 May;11(5):489-96 [PMID: 19324921]
  10. Echocardiography. 2002 Nov;19(8):655-9 [PMID: 12487634]
  11. J Am Coll Cardiol. 2018 Mar 27;71(12):1297-1308 [PMID: 29566812]
  12. Echocardiography. 2014 Apr;31(4):428-33 [PMID: 24152252]
  13. Circulation. 2002 Aug 13;106(7):809-13 [PMID: 12176952]
  14. Circ Cardiovasc Imaging. 2022 May;15(5):e013558 [PMID: 35580160]
  15. Eur Heart J. 2016 Jun 1;37(21):1642-50 [PMID: 26417058]
  16. J Clin Med. 2021 Jul 30;10(15): [PMID: 34362186]
  17. Circ Cardiovasc Imaging. 2020 May;13(5):e010356 [PMID: 32370617]
  18. Eur Heart J Cardiovasc Imaging. 2020 Apr 1;21(4):357-362 [PMID: 32196100]
  19. J Clin Med. 2021 Aug 17;10(16): [PMID: 34441937]
  20. J Am Coll Cardiol. 2009 Dec 8;54(24):2251-60 [PMID: 19958961]
  21. J Card Fail. 2007 Dec;13(10):836-42 [PMID: 18068617]
  22. Minerva Cardiol Angiol. 2022 Apr;70(2):148-159 [PMID: 32657562]
  23. J Clin Med. 2021 Jun 29;10(13): [PMID: 34209955]
  24. Am J Cardiol. 2019 Sep 15;124(6):972-977 [PMID: 31324358]
  25. J Am Soc Echocardiogr. 2017 Aug;30(8):736-744 [PMID: 28599829]
  26. Circulation. 2019 Oct;140(14):1156-1169 [PMID: 31510787]
  27. J Am Soc Echocardiogr. 2019 Jun;32(6):730-736 [PMID: 31171107]
  28. Eur Heart J. 2017 Sep 21;38(36):2739-2791 [PMID: 28886619]
  29. J Am Heart Assoc. 2023 May 2;12(9):e029337 [PMID: 37119067]
  30. Heart Lung Circ. 2020 Dec;29(12):1773-1781 [PMID: 32362405]
  31. J Am Coll Cardiol. 2009 May 19;53(20):1865-73 [PMID: 19442886]
  32. Circulation. 2006 Apr 11;113(14):1738-44 [PMID: 16585393]
  33. Front Cardiovasc Med. 2022 Nov 16;9:964669 [PMID: 36465454]
  34. Clin Physiol Funct Imaging. 2009 Nov;29(6):447-52 [PMID: 19712079]
  35. Am J Cardiol. 2014 May 1;113(9):1536-42 [PMID: 24641965]
  36. J Am Coll Cardiol. 2016 May 17;67(19):2263-2288 [PMID: 27049682]
  37. Circulation. 2003 Jul 22;108(3):319-24 [PMID: 12835219]
  38. J Am Coll Cardiol. 2001 Jun 15;37(8):2101-7 [PMID: 11419894]
  39. J Cardiovasc Comput Tomogr. 2022 Jan-Feb;16(1):54-122 [PMID: 34955448]
  40. Heart. 2022 Dec 13;109(1):47-54 [PMID: 35977812]
  41. Eur J Echocardiogr. 2008 Jul;9(4):415-37 [PMID: 18579481]
  42. JACC Cardiovasc Imaging. 2020 Oct;13(10):2085-2095 [PMID: 32682714]
  43. EuroIntervention. 2016 Oct 10;12(8):e1047-e1056 [PMID: 26610809]
  44. Eur Heart J Cardiovasc Imaging. 2016 Nov;17(11):1191-1229 [PMID: 27880640]
  45. Heart. 2020 Dec;106(23):1792-1797 [PMID: 32747494]
  46. JACC Cardiovasc Imaging. 2015 Jun;8(6):724-36 [PMID: 26068289]
  47. J Am Heart Assoc. 2019 Mar 19;8(6):e011168 [PMID: 30879370]
  48. Eur Heart J. 2012 Oct;33(19):2451-96 [PMID: 22922415]
  49. JAMA Cardiol. 2019 Jan 1;4(1):64-70 [PMID: 30566185]
  50. JACC Cardiovasc Imaging. 2018 Nov;11(11):1692-1705 [PMID: 30409330]
  51. J Am Heart Assoc. 2018 Apr 13;7(8): [PMID: 29654191]
  52. JACC Cardiovasc Interv. 2020 Sep 28;13(18):2134-2136 [PMID: 32972575]
  53. Heart. 2023 Mar 27;109(8):634-642 [PMID: 36598073]
  54. J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14 [PMID: 25559473]
  55. Eur Heart J. 2022 Feb 12;43(7):561-632 [PMID: 34453165]
  56. J Am Coll Cardiol. 2000 Nov 15;36(6):1889-96 [PMID: 11092661]
  57. Circ Cardiovasc Imaging. 2019 May;12(5):e008353 [PMID: 31088148]
  58. Catheter Cardiovasc Interv. 2019 Mar 1;93(4):707-712 [PMID: 30280469]
  59. Eur Heart J Cardiovasc Imaging. 2014 Feb;15(2):158-63 [PMID: 23907344]
  60. Eur Heart J. 2014 Apr;35(16):1033-40 [PMID: 24126880]
  61. JACC Cardiovasc Imaging. 2015 Mar;8(3):380-382 [PMID: 25459306]
  62. JACC Cardiovasc Imaging. 2013 Feb;6(2):175-83 [PMID: 23489531]
  63. JAMA Cardiol. 2020 Oct 1;5(10):1102-1112 [PMID: 32639521]
  64. Eur Heart J Qual Care Clin Outcomes. 2023 Jan 20;: [PMID: 36669758]
  65. Circulation. 2022 Mar;145(9):648-658 [PMID: 34779220]
  66. Circ Cardiovasc Interv. 2019 Aug;12(8):e007547 [PMID: 31416359]
  67. J Cardiovasc Echogr. 2020 Apr-Jun;30(2):52-61 [PMID: 33282641]
  68. J Thorac Cardiovasc Surg. 2021 Aug;162(2):e183-e353 [PMID: 33972115]
  69. J Am Coll Cardiol. 2019 Nov 5;74(18):2278-2291 [PMID: 31672185]
  70. Eur Heart J. 2017 Dec 01;38(45):3351-3358 [PMID: 29020232]
  71. Eur Heart J. 2021 Oct 1;42(37):3869-3878 [PMID: 34449837]

Word Cloud

Created with Highcharts 10.0.0ASSEaorticstressechocardiographysevere<LVLFLGreservesymptomsvalvegradientAVA0LVEFevaluatingroleevaluationvalvularheartdiseasestenosisechocardiographictransvalvularthree1cmpeakvelocity>4m/smeanmmHgreducedflowsystoliccontractileCRpatientsclassicalasymptomaticcomprehensiveassessmentfunctionABCDEGRestplayspivotaluserecommendedmismatchrestingtransthoracicfindingsrestanalysisstepwiseapproachbeginsmorphologyproceedsmeasurementareausingcontinuityequationsplanimetrypresencefollowingcriteriasuggestsAS:40Howeverapproximatelyonecasescanobservediscordant<40dueassociateddysfunction50%defined"classical"low-flowlow-gradientnormal"paradoxical"establisheddistinguishedpseudo-severetrulyobservationaldatasuggestlong-termprognosismayfavorablepreviouslythoughtofferingwindowopportunityinterventionprioronsetThereforeguidelinesrecommendexercisephysicallyactiveparticularlyyounger70yearssymptomaticlow-dosedobutamineincludesgradientsglobalpulmonarycongestionintegratesconsiderationsbloodpressureresponsechronotropicStressEcho2030prospectivelarge-scalestudyemploysprotocolanalyzeclinicalphenotypescapturingvariousvulnerabilitysourcessupportecho-driventreatmentstrategiesStressEchocardiographyAorticStenosiscoronaryleftventricular

Similar Articles

Cited By